PRECIPIO, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
PRECIPIO, INC. (PRPO) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $70.00 thousand as of 2018-12-31, per its 10-K filed 2020-03-27.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2020-03-27
- 2018-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $70.00K.
- 2017-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $349.00K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2018-12-31 | $70.00K 10-K · filed 2020-03-27 |
| 2017-12-31 | $349.00K 10-K · filed 2019-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |